Drug Profile
Research programme: combination therapies - Angiotech/CombinatoRx
Latest Information Update: 13 Apr 2010
Price :
$50
*
At a glance
- Originator Angiotech Pharmaceuticals; CombinatoRx
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Joint disorders; Peripheral arterial disorders; Vascular disorders; Vascular restenosis
Most Recent Events
- 08 Jul 2009 Preclinical development is ongoing in USA and Canada
- 13 Jun 2007 CombinatoRx and Angiotech have extended their research and development collaboration
- 03 Oct 2005 Preclinical trials in Joint disorders in Canada (unspecified route)